EGRX Quote, Financials, Valuation and Earnings

Nanoviricides has a net margin of -- compared to Eagle Pharmaceuticals's net margin of --. Eagle Pharmaceuticals's return on equity of -- beat Nanoviricides's return on equity of --.

Eagle Pharmaceuticals has a consensus price target of --, signalling upside risk potential of 762.94%. On the other hand Nanoviricides has an analysts' consensus of -- which suggests that it could grow by 387.4%. Given that Eagle Pharmaceuticals has higher upside potential than Nanoviricides, analysts believe Eagle Pharmaceuticals is more attractive than Nanoviricides.

Eagle Pharmaceuticals has a beta of 0.828, which suggesting that the stock is 17.248% less volatile than S&P 500. In comparison Nanoviricides has a beta of 0.927, suggesting its less volatile than the S&P 500 by 7.287%.

Eagle Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nanoviricides offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Eagle Pharmaceuticals pays -- of its earnings as a dividend. Nanoviricides pays out -- of its earnings as a dividend.

Eagle Pharmaceuticals quarterly revenues are --, which are smaller than Nanoviricides quarterly revenues of --. Eagle Pharmaceuticals's net income of -- is lower than Nanoviricides's net income of -$2M. Notably, Eagle Pharmaceuticals's price-to-earnings ratio is -- while Nanoviricides's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Eagle Pharmaceuticals is 0.10x versus -- for Nanoviricides. Usually stocks with elevated PS ratios are considered overvalued.

Oragenics has a net margin of -- compared to Eagle Pharmaceuticals's net margin of --. Eagle Pharmaceuticals's return on equity of -- beat Oragenics's return on equity of --.

Eagle Pharmaceuticals has a consensus price target of --, signalling upside risk potential of 762.94%. On the other hand Oragenics has an analysts' consensus of $1.00 which suggests that it could grow by 415.46%. Given that Eagle Pharmaceuticals has higher upside potential than Oragenics, analysts believe Eagle Pharmaceuticals is more attractive than Oragenics.

Eagle Pharmaceuticals has a beta of 0.828, which suggesting that the stock is 17.248% less volatile than S&P 500. In comparison Oragenics has a beta of 0.868, suggesting its less volatile than the S&P 500 by 13.16%.

Eagle Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Eagle Pharmaceuticals pays -- of its earnings as a dividend. Oragenics pays out -- of its earnings as a dividend.

Eagle Pharmaceuticals quarterly revenues are --, which are smaller than Oragenics quarterly revenues of --. Eagle Pharmaceuticals's net income of -- is lower than Oragenics's net income of -$3.3M. Notably, Eagle Pharmaceuticals's price-to-earnings ratio is -- while Oragenics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Eagle Pharmaceuticals is 0.10x versus 1.21x for Oragenics. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -- compared to Eagle Pharmaceuticals's net margin of --. Eagle Pharmaceuticals's return on equity of -- beat Palatin Technologies's return on equity of --.

Eagle Pharmaceuticals has a consensus price target of --, signalling upside risk potential of 762.94%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 3489.74%. Given that Palatin Technologies has higher upside potential than Eagle Pharmaceuticals, analysts believe Palatin Technologies is more attractive than Eagle Pharmaceuticals.

Eagle Pharmaceuticals has a beta of 0.828, which suggesting that the stock is 17.248% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.896, suggesting its less volatile than the S&P 500 by 10.45%.

Eagle Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Eagle Pharmaceuticals pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

Eagle Pharmaceuticals quarterly revenues are --, which are smaller than Palatin Technologies quarterly revenues of --. Eagle Pharmaceuticals's net income of -- is lower than Palatin Technologies's net income of --. Notably, Eagle Pharmaceuticals's price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Eagle Pharmaceuticals is 0.10x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Theriva Biologics has a net margin of -- compared to Eagle Pharmaceuticals's net margin of --. Eagle Pharmaceuticals's return on equity of -- beat Theriva Biologics's return on equity of --.

Eagle Pharmaceuticals has a consensus price target of --, signalling upside risk potential of 762.94%. On the other hand Theriva Biologics has an analysts' consensus of $6.00 which suggests that it could grow by 319.58%. Given that Eagle Pharmaceuticals has higher upside potential than Theriva Biologics, analysts believe Eagle Pharmaceuticals is more attractive than Theriva Biologics.

Eagle Pharmaceuticals has a beta of 0.828, which suggesting that the stock is 17.248% less volatile than S&P 500. In comparison Theriva Biologics has a beta of 1.169, suggesting its more volatile than the S&P 500 by 16.92%.

Eagle Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Eagle Pharmaceuticals pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.

Eagle Pharmaceuticals quarterly revenues are --, which are smaller than Theriva Biologics quarterly revenues of --. Eagle Pharmaceuticals's net income of -- is lower than Theriva Biologics's net income of -$4.4M. Notably, Eagle Pharmaceuticals's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Eagle Pharmaceuticals is 0.10x versus 0.63x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.